Blood and blood product use during COVID-19 infection
- PMID: 32279352
- PMCID: PMC7262362
- DOI: 10.1002/ajh.25823
Blood and blood product use during COVID-19 infection
Conflict of interest statement
All authors declare no competing interests. This study was approved by the National Healthcare Group Domain Specific Review Board (DSRB).
Figures
) Symptomatic, not admitted; (
) isolation ward; (
) high dependency, high flow oxygen; (
) ICU, mechanical ventilation; (
) death; B, packed red blood cells; P, platelets; F, fresh frozen plasma; E, extracorporeal membrane oxygenation; *, oxygen; ^, platelet clumpsReferences
-
- Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID‐19) WHO Interim guidance, March 2020. https://www.who.int/publications‐detail/maintaining‐a‐safe‐and‐adequate‐....
-
- Gschwender AN, Gillard L. Disaster preparedness in the blood bank. Am Soc Clin Lab Sci. 2017;30(4):250‐257. 10.29074/ascls.30.4.250. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical